Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancers

A three-protein biomarker panel assessed in diagnostic tissue predicts death from prostate cancer for men with localized disease

(2014) Gianluca Severi et al.   Cancer Medicine

The fat side of prostate cancer

(2013) Giorgia Zadra et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

Integrative Genomic Analyses Reveal an Androgen-Driven Somatic Alteration Landscape in Early-Onset Prostate Cancer

(2013) Joachim Weischenfeldt et al.   CANCER CELL

CHD1 Is a 5q21 Tumor Suppressor Required for ERG Rearrangement in Prostate Cancer

(2013) L. Burkhardt et al.   CANCER RESEARCH

Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressiveERGfusion-positive prostate cancers

(2013) Antje Krohn et al.   JOURNAL OF PATHOLOGY

Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions

(2013) Martina Kluth et al.   MODERN PATHOLOGY

Characterization of Transcriptional Changes in ERG Rearrangement-Positive Prostate Cancer Identifies the Regulation of Metabolic Sensors Such as Neuropeptide Y

(2013) Petra Massoner et al.   PLoS One

Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate Cancer

(2012) Antje Krohn et al.   AMERICAN JOURNAL OF PATHOLOGY

PTENgenomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity

(2012) Khalil Choucair et al.   BMC CANCER

Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence

(2012) Katharina Grupp et al.   MODERN PATHOLOGY

Utility of RhoC and ZAG protein expression as biomarkers for prediction of pSa failure following radical prostatectomy for high grade prostate cancer

(2012) John Mills et al.   PATHOLOGY

ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy

(2011) Sarah Minner et al.   CLINICAL CANCER RESEARCH

GATA2 negatively regulates PTEN by preventing nuclear translocation of androgen receptor and by androgen-independent suppression of PTEN transcription in breast cancer

(2011) Yu Wang et al.   HUMAN MOLECULAR GENETICS

The genomic complexity of primary human prostate cancer

(2011) Michael F. Berger et al.   NATURE

Low AZGP1 expression predicts for recurrence in margin-positive, localized prostate cancer

(2011) Po Yee Yip et al.   PROSTATE

Integrative Genomic Profiling of Human Prostate Cancer

(2010) Barry S. Taylor et al.   CANCER CELL

A role for GATA-2 in transition to an aggressive phenotype in prostate cancer through modulation of key androgen-regulated genes

(2009) M Böhm et al.   ONCOGENE

2D-DIGE as a Strategy To Identify Serum Markers for the Progression of Prostate Cancer

(2008) Jennifer C. Byrne et al.   JOURNAL OF PROTEOME RESEARCH

Clinical significance of p53 alterations in surgically treated prostate cancers

(2008) Thorsten Schlomm et al.   MODERN PATHOLOGY

A Tissue Biomarker Panel Predicting Systemic Progression after PSA Recurrence Post-Definitive Prostate Cancer Therapy

(2008) Tohru Nakagawa et al.   PLoS One